Gavin Giovannoni

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations

Rheumatology, Relapsing-remitting Multiple Sclerosis, Immunology +8

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

Eva Havrdová, Steven Galetta, Michael Hutchinson et al. · The Lancet Neurology · 2009 · 470 citations

Rheumatology, Radiological Disease Activity, Systemic Scleroderma +7

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

David H. Miller, Derek Soon, Kryshani Fernando et al. · Neurology · 2007 · 330 citations

The incidence and significance of anti-natalizumab antibodies

Peter A. Calabresi, Gavin Giovannoni, Christian Confavreux et al. · Neurology · 2007 · 329 citations

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Ralf Gold, Gavin Giovannoni, Krzysztof Selmaj et al. · The Lancet · 2013 · 285 citations

Relapsing-remitting Multiple Sclerosis, Clinical Trials, Treatment Option +7